SEC Company Response from KIORA PHARMACEUTICALS INC (KPRX) (CIK 0001372514) (KPRX) — Feb 10, 2015
KIORA PHARMACEUTICALS INC (KPRX) (CIK 0001372514)
Date: Feb. 10, 2015 · CIK: 0001372514 · Accession: 0001144204-15-007389
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-197725
Letter
Eyegate Pharmaceuticals, Inc.
Waverley Oaks Road
Suite 108
Waltham, MA 02452
February 10, 2015
United States Securities and Exchange Commission
Divison of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Re: Eyegate Pharmaceuticals, Inc.
Registration Statement on Form S-1
File No. 333-197725
Request for Acceleration
Ladies and Gentlemen:
Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Eyegate Pharmaceuticals, Inc. (the “Registrant”) hereby requests acceleration of the effective date of its Registration Statement on Form S-1 (File No. 333-197725), as amended (the “Registration Statement”), so that it may become effective at 4:30 p.m. Eastern time on February 12, 2015, or as soon thereafter as practicable. Under separate cover, you will receive a letter from the lead underwriter of the proposed offering joining the Registrant’s request for acceleration of effectiveness of the Registration Statement.
The Registrant hereby acknowledges that:
(a)
should the Securities and Exchange Commission (the “Commission”) or the staff, acting pursuant to delegated authority, declare the Registration Statement effective, it does not foreclose the Commission from taking any action with respect to the Registration Statement;
(b)
the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the Registration Statement effective, does not relieve the Registrant from its full responsibility for the adequacy and accuracy of the disclosure in the Registration Statement; and
(c)
the Registrant may not assert staff comments and the declaration of effectiveness of the Registration Statement as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Very truly yours,
Eyegate Pharmaceuticals, Inc.
Show Raw Text
CORRESP
1
filename1.htm
Eyegate
Pharmaceuticals, Inc.
271
Waverley Oaks Road
Suite 108
Waltham, MA 02452
February 10, 2015
United States Securities and Exchange Commission
Divison of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Re: Eyegate Pharmaceuticals, Inc.
Registration Statement on Form S-1
File No. 333-197725
Request for Acceleration
Ladies and Gentlemen:
Pursuant to Rule 461 promulgated under the
Securities Act of 1933, as amended, Eyegate Pharmaceuticals, Inc. (the “Registrant”) hereby requests
acceleration of the effective date of its Registration Statement on Form S-1 (File No. 333-197725), as amended (the
“Registration Statement”), so that it may become effective at 4:30 p.m. Eastern time on February 12,
2015, or as soon thereafter as practicable. Under separate cover, you will receive a letter from the lead underwriter of the
proposed offering joining the Registrant’s request for acceleration of effectiveness of the Registration Statement.
The Registrant hereby acknowledges
that:
(a)
should the Securities and Exchange Commission (the “Commission”) or the staff, acting pursuant to delegated authority, declare the Registration Statement effective, it does not foreclose the Commission from taking any action with respect to the Registration Statement;
(b)
the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the Registration Statement effective, does not relieve the Registrant from its full responsibility for the adequacy and accuracy of the disclosure in the Registration Statement; and
(c)
the Registrant may not assert staff comments and the declaration of effectiveness of the Registration Statement as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Very truly yours,
Eyegate Pharmaceuticals, Inc.
By:
/s/ Stephen From
Name:
Title:
Stephen From
President and Chief Executive Officer